目的 觀察十一味參芪聯(lián)合重組人粒細(xì)胞刺激因子治療化療后中性粒細(xì)胞減少癥的臨床療效。方法 選取2016年7月-2017年7月天津市第五中心醫(yī)院（北京大學(xué)濱海醫(yī)院）收治的161例腫瘤化療后中性粒細(xì)胞減少癥患者，隨機分為對照組（80例）和治療組（81例）。對照組患者皮下注射重組人粒細(xì)胞刺激因子注射液，5 μg/kg，1次/d。治療組患者在對照組治療基礎(chǔ)上口服十一味參芪片，4片/次，3次/d。兩組患者均連續(xù)治療7 d。觀察兩組的臨床療效，比較兩組的中性粒細(xì)胞計數(shù)、QOL評分和KPS評分的變化情況。結(jié)果 治療后，對照組和治療組的總有效率分別為85.00%、96.30%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療3、7 d，兩組患者中性粒細(xì)胞計數(shù)均較治療前顯著升高，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；治療3、7 d，治療組中性粒細(xì)胞計數(shù)顯著高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者QOL評分和KPS評分均顯著升高，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；治療后，治療組患者QOL評分和KPS評分較顯著高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 十一味參芪片聯(lián)合重組人粒細(xì)胞刺激因子治療化療后中性粒細(xì)胞減少癥具有較好的臨床療效，可改善患者的生活質(zhì)量和身體功能狀態(tài)，具有一定的臨床推廣應(yīng)用價值。

Objective To observe the clinical effect of Shiyiwei Shenqi Tablets combined with recombinant human granulocyte colony-stimulating factor in treatment of neutropenia after chemotherapy. Methods Patients (161 cases) with neutropenia after chemotherapy in Tianjin Fifth Central Hospital (Binhai Hospital of Peking University) from July 2016 to July 2017 were randomly divided into control (80 cases) and treatment (81 cases) groups. Patients in the control group were sc administered with Recombinant Human Granulocyte Colony-stimulating Factor Injection, 5 μg/kg, once daily. Patients in the treatment group were po administered with Shiyiwei Shenqi Tablets, 4 tablets/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy was evaluated, and the changes of neutrophil count, QOL score, and KPS score in two groups were compared. Results After treatment, the clinical efficacy in the control group were 85.00% and 96.30%, and there were differences between two groups (P<0.05). Treatment for 3 d and 7 d, the neutrophil count in two groups were significantly increased, and there were differences in the same group (P<0.05). Treatment for 3 d and 7 d, the neutrophil count in the treatment group was higher than that in the control group, and there were differences between two groups (P<0.05). After treatment, QOL score and KPS score in two groups were significantly increased, and there were differences between two groups (P<0.05). After treatment, QOL score and KPS score in the treatment group was higher than that in the control group, and there were differences between two groups (P<0.05). Conclusion Shiyiwei Shenqi Tablets combined with recombinant human granulocyte colony-stimulating factor has significant clinical effect in treatment of neutropenia after chemotherapy, and can improve the life quality and body functional state, which has a certain clinical application value.